TOP TEN perturbations for 38866_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38866_at
Selected probe(set): 208406_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38866_at (208406_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

T-helper activation study 1 (120min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.434824
Number of Samples:2 / 2
Experimental T-helper activation study 1 (120min)
Alloantigen specific helper T-cells were stimulated for 120min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-1.9865026
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

T-helper activation study 1 (100min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):1.847518
Number of Samples:2 / 2
Experimental T-helper activation study 1 (100min)
Alloantigen specific helper T-cells were stimulated for 100min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-1.8427391
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Treg activation study 1 (300min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-1.759697
Number of Samples:2 / 2
Experimental Treg activation study 1 (300min)
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

pediatric meningococcal sepsis study 1 (24h; blood) / normal blood sample

Relative Expression (log2-ratio):-1.7429514
Number of Samples:3 / 3
Experimental pediatric meningococcal sepsis study 1 (24h; blood)
Blood samples collected from children with (suspected) meningococcal sepsis 24 hours after admission to the pediatric intensive care unit (PICU).
Control normal blood sample
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI.

precursor-B-ALL study 3 (TEL-AML1) / T-ALL study 3

Relative Expression (log2-ratio):-1.7249584
Number of Samples:15 / 29
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

methyl methanesulfonate study 6 (320µM) / untreated TK6 cell sample

Relative Expression (log2-ratio):-1.685566
Number of Samples:3 / 15
Experimental methyl methanesulfonate study 6 (320µM)
TK6 cells treated with 320µM methyl methanesulfonate for 24h. ATC code:---
Control untreated TK6 cell sample
Untreated TK6 cell line. Cells where left untreated for 24h before harvesting.

precursor-B-ALL study 3 (E2A-PBX1) / T-ALL study 3

Relative Expression (log2-ratio):-1.6639795
Number of Samples:6 / 29
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (BCR-ABL) / T-ALL study 3

Relative Expression (log2-ratio):-1.651474
Number of Samples:4 / 29
Experimental precursor-B-ALL study 3 (BCR-ABL)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).